HEPASOF (400 mg),Sovaldi

Comparative Randomized, Single Dose, Two-Way Crossover, Open-Label Study to Determine the Bioequivalence of Sofosbuvir 400 mg Tablets Formulations, Sovaldi and HEPASOF (400 mg), after Oral Administration to Healthy Thai Volunteers under Fasting Conditions

An Open Label, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Crossover, Fully Replicate Bioequivalence Study of HEPASOF (400 mg) (Sofosbuvir 400 mg Tablets) of The Government Pharmaceutical Organization, Bangkok, Thailand with Sovaldi (Sofosbuvir 400 mg Tablets) of Patheon Inc., Canada in Normal, Healthy, Adult Human Subjects under Fasting Conditions